Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators DOI Creative Commons
Yu Kyung Jun, Hyuk Yoon

Korean Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 84(2), P. 51 - 64

Published: Aug. 23, 2024

Small molecules, including Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor modulators (S1PRMs), are promising new treatments for inflammatory bowel disease (IBD). molecules exhibit more predictable pharmacokinetics than biologics, less likely to induce immune responses, can be administered orally. JAK function by blocking the activity of enzymes, which prevents subsequent phosphorylation activation signal transducer activator transcription (STAT) proteins. Tofacitinib filgotinib approved treating ulcerative colitis (UC), while upadacitinib is UC Crohn's disease. Nevertheless, increase risk herpes zoster, cancer, major adverse cardiovascular events, venous thromboembolism. S1PRMs bind S1PRs, particularly S1PR1, on lymphocytes. This interaction inhibits lymphocytes from exiting lymph nodes migrating gut, thereby reducing inflammation response in intestinal mucosa. Ozanimod etrasimod treatment UC, but they cause side effects such as bradycardia, conduction disorder, macular edema. Overall, offer significant benefits managing IBD, although their potential require careful monitoring.

Language: Английский

Autism spectrum disorder and a possible role of anti-inflammatory treatments: experience in the pediatric allergy/immunology clinic DOI Creative Commons

Harumi Jyonouchi

Frontiers in Psychiatry, Journal Year: 2024, Volume and Issue: 15

Published: June 24, 2024

Autism spectrum disorder (ASD 1 ) is a behaviorally defined syndrome encompassing markedly heterogeneous patient population. Many ASD subjects fail to respond the st line behavioral and pharmacological interventions, leaving parents seek out other treatment options. Evidence supports that neuroinflammation plays role in pathogenesis. However, underlying mechanisms likely vary for each patient, influenced by genetic, epigenetic, environmental factors. Although anti-inflammatory measures, mainly based on metabolic changes oxidative stress, have provided promising results some subjects, use of such measures requires careful selection clinical laboratory findings. Recent progress neuroscience molecular immunology has made it possible allow re-purposing currently available medications, used autoimmune chronic inflammatory conditions, as options subjects. On hand, emerging including biologic gate-keeper blockers, exert powerful effects specific mediators or signaling pathways. It will require both keen understanding action agents patients suitable treatment. This review attempt summarize already targeting patients, then applicable scientific rationale trial data, if available. In our experience, were treated under diagnoses autoimmune/autoinflammatory conditions and/or post-infectious neuroinflammation. there are little data specifically Therefore, these immunomodulating potential be discussed preclinical case reports, generated with medical conditions. hopefully highlight expanding scope treating

Language: Английский

Citations

3
Current and emerging drugs for the treatment of pruritus: an update of the literature DOI
Rami H. Mahmoud, Sarah G Brooks, Gil Yosipovitch

et al.

Expert Opinion on Pharmacotherapy, Journal Year: 2024, Volume and Issue: 25(6), P. 655 - 672

Published: April 12, 2024

Pruritus, particularly in its chronic form, often imposes significant suffering and reductions patients' quality of life. The pathophysiology itch is varied depending on disease context, creating opportunities for unique drug development multimodal therapy.

Language: Английский

Citations

2
Pharmacokinetics, Safety, Tolerability, and Exploratory Efficacy of Upadacitinib in Children with Severe Atopic Dermatitis DOI
Yuli Qian,

Eliza M. Raymundo,

Shuai Hao

et al.

Clinical Therapeutics, Journal Year: 2024, Volume and Issue: 46(10), P. 733 - 741

Published: Aug. 13, 2024

Language: Английский

Citations

2
Case report: Successful remission with upadacitinib in a young patient with anti-TNF-refractory intestinal Behçet’s disease DOI Creative Commons

Sumei Sha,

Bin Xu, Kairuo Wang

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 8, 2024

The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behçet's disease complicate its management, with the absence standardized guidelines further exacerbating challenges faced by clinicians.

Language: Английский

Citations

2
Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators DOI Creative Commons
Yu Kyung Jun, Hyuk Yoon

Korean Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 84(2), P. 51 - 64

Published: Aug. 23, 2024

Small molecules, including Janus kinase (JAK) inhibitors and sphingosine-1-phosphate receptor modulators (S1PRMs), are promising new treatments for inflammatory bowel disease (IBD). molecules exhibit more predictable pharmacokinetics than biologics, less likely to induce immune responses, can be administered orally. JAK function by blocking the activity of enzymes, which prevents subsequent phosphorylation activation signal transducer activator transcription (STAT) proteins. Tofacitinib filgotinib approved treating ulcerative colitis (UC), while upadacitinib is UC Crohn's disease. Nevertheless, increase risk herpes zoster, cancer, major adverse cardiovascular events, venous thromboembolism. S1PRMs bind S1PRs, particularly S1PR1, on lymphocytes. This interaction inhibits lymphocytes from exiting lymph nodes migrating gut, thereby reducing inflammation response in intestinal mucosa. Ozanimod etrasimod treatment UC, but they cause side effects such as bradycardia, conduction disorder, macular edema. Overall, offer significant benefits managing IBD, although their potential require careful monitoring.

Language: Английский

Citations

1